tranScrip
Linda Summerton's work experience includes:
- Board Member at One Nucleus since February 2017.
- Senior Partner and Head of Scientific Affairs & Oncology at tranScrip since August 2014.
- Governor at Abbot's Hill since 2014.
- CEO at Immodulon Therapeutics Ltd from April 2016 to June 2017.
- CEO at Dialog Devices Ltd from July 2014 to September 2016.
- Partner at Celtic Pharma Holdings Advisors LLP from December 2008 to April 2014.
- Therapy Area Head at Celtic Pharma from August 2007 to December 2009.
- SVP Portfolio and Project Management at Merck KGaA Pharma Ethicals from January 2006 to July 2007.
- Executive Director, Portfolio Strategy at AstraZeneca Pharmaceuticals from May 2003 to December 2005.
- Global Product Director, Oncology at AstraZeneca Pharmaceuticals from June 1999 to May 2003.
- Clinical Manager at Zeneca Pharmaceuticals from June 1995 to June 1999.
- Global Project Manager at Zeneca Pharmaceuticals from January 1992 to June 1995.
Linda Summerton earned an MA and PhD in Chemistry from the University of Cambridge between 1980 and 1986. Linda then pursued a postdoctoral program in Structural Biochemistry at the University of California, San Francisco from 1987 to 1988.
This person is not in any offices
tranScrip
tranScrip is a leading contract drug development organisation which supports pharma and biotech companies in the development and lifecycle of medicines. We bring innovative solutions to clients’ global drug development needs. From translational medicine through to registration and post licencing, we deliver both strategic leadership and operational execution of development programmes, covering clinical, regulatory, drug safety, and commercial elements. Our teams of physicians, scientists and regulatory experts, help clients select the most promising drug candidates and bring them to the market. We guide our clients through their decision making from first in man studies to proof of concept and pivotal trials, regulatory submissions and product launches. In the last decade, tranScrip has supported over 250 clients and has been integral to many development programmes and regulatory submissions, bringing products to the market each year across a wide range of therapeutic areas.